% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{HtterKrnke:276189,
      author       = {M. L. Hütter-Krönke and A. Neagoie and I. W. Blau and V.
                      Wais and L. Vuong and A. Gantner and J. Ahn and O. Penack
                      and J. Schnell and K. A. Nogai and B. Eberspächer and M.
                      Saadati and A. Benner$^*$ and L. Bullinger$^*$ and H.
                      Döhner and D. Bunjes and E. Sala},
      title        = {{R}isk factors and characteristics influencing humoral
                      response to {COVID}-19 vaccination in patients after
                      allogeneic stem cell transplantation.},
      journal      = {Frontiers in immunology},
      volume       = {14},
      issn         = {1664-3224},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2023-01011},
      pages        = {1174289},
      year         = {2023},
      abstract     = {Vaccination against severe acute respiratory syndrome
                      coronavirus type 2 (SARS-CoV-2) is approved and recommended
                      for immunocompromised patients such as patients after
                      allogeneic stem cell transplantation (allo-SCT). Since
                      infections represent a relevant cause of transplant related
                      mortality we analyzed the advent of immunization to
                      SARS-CoV-2 vaccination in a bicentric population of
                      allogeneic transplanted patients.We retrospectively analyzed
                      data of allo-SCT recipients in two German transplantation
                      centers for safety and serologic response after two and
                      three SARS-CoV-2 vaccinations. Patients received mRNA
                      vaccines or vector-based vaccines. All patients were
                      monitored for antibodies against SARS-CoV2-spike protein
                      (anti-S-IgG) with an IgG ELISA assay or an EIA Assay after
                      two and three doses of vaccination.A total of 243 allo-SCT
                      patients underwent SARS-CoV-2 vaccination. The median age
                      was 59 years (range 22-81). While $85\%$ of patients
                      received two doses of mRNA vaccines, $10\%$ had vector-based
                      vaccines and $5\%$ received a mixed vaccination. The two
                      vaccine doses were well tolerated with only $3\%$ patients
                      developing a reactivation of graft versus host disease
                      (GvHD). Overall, $72\%$ of patients showed a humoral
                      response after two vaccinations. In the multivariate
                      analysis age at time of allo-SCT (p=0.0065), ongoing
                      immunosuppressive therapy (p= 0.029) and lack of immune
                      reconstitution (CD4-T-cell counts <200/μl, p< 0.001) were
                      associated with no response. Sex, intensity of conditioning
                      and the use of ATG showed no influence on seroconversion.
                      Finally, 44 out of 69 patients that did not respond after
                      the second dose received a booster and $57\%$ (25/44) showed
                      a seroconversion.We showed in our bicentric allo-SCT patient
                      cohort, that a humoral response could be achieve after the
                      regular approved schedule, especially for those patients who
                      underwent immune reconstitution and were free from
                      immunosuppressive drugs. In over $50\%$ of the initial
                      non-responders after 2-dose vaccination, a seroconversion
                      can be achieved by boostering with a third dose.},
      keywords     = {COVID 19-vaccination (Other) / SARS-CoV-2 antibodies
                      (Other) / SARS-CoV-2-vaccination (Other) / allogeneic stem
                      cell transplantation (Other) / booster (Other) / humoral
                      response (Other) / vaccine (Other)},
      cin          = {BE01 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37207199},
      pmc          = {pmc:PMC10190126},
      doi          = {10.3389/fimmu.2023.1174289},
      url          = {https://inrepo02.dkfz.de/record/276189},
}